Abstract

Non-invasive, molecularly-specific, focal modulation of brain circuits with low off-target effects can lead to breakthroughs in treatments of brain disorders. We systemically inject engineered ultrasound-controllable drug carriers and subsequently apply a novel two-component Aggregation and Uncaging Focused Ultrasound Sequence (AU-FUS) at the desired targets inside the brain. The first sequence aggregates drug carriers with millimeter-precision by orders of magnitude. The second sequence uncages the carrier’s cargo locally to achieve high target specificity without compromising the blood-brain barrier (BBB). Upon release from the carriers, drugs locally cross the intact BBB. We show circuit-specific manipulation of sensory signaling in motor cortex in rats by locally concentrating and releasing a GABAA receptor agonist from ultrasound-controlled carriers. Our approach uses orders of magnitude (1300x) less drug than is otherwise required by systemic injection and requires very low ultrasound pressures (20-fold below FDA safety limits for diagnostic imaging). We show that the BBB remains intact using passive cavitation detection (PCD), MRI-contrast agents and, importantly, also by sensitive fluorescent dye extravasation and immunohistochemistry.

Highlights

  • Non-invasive, molecularly-specific, focal modulation of brain circuits with low off-target effects can lead to breakthroughs in treatments of brain disorders

  • Mediated blood-brain barrier (BBB) opening might be acceptable for one-time acute delivery of viral vectors or other macromolecules, it is currently unclear what risks repeated BBB opening may pose for long-term treatment of neurological and neuropsychiatric disorders

  • Since BBB opening on its own modulates neuronal activity and behavior in rodents and primates[21,22,23], it cannot be used in circuit investigations without confounding effects

Read more

Summary

Introduction

Non-invasive, molecularly-specific, focal modulation of brain circuits with low off-target effects can lead to breakthroughs in treatments of brain disorders. Current methods under development to target specific brain circuits such as transcranial magnetic stimulation (TMS) or penetrating electrodes (i.e., deepbrain stimulation; DBS) lack cellular and molecular specificity while either have low spatial resolution, or are invasive[5] To address this challenge, we developed a unique spatiallytargeted and molecularly-specific drug delivery technology by using novel focused ultrasound (FUS) sequences and ultrasoundsensitive drug carriers. FUS has been combined with microbubbles to open the blood–brain barrier (BBB) locally to deliver molecules that otherwise do not cross the intact BBB8–10 This is a promising development for acute delivery of macromolecules and has significant potential, in the treatment of genetic disorders when used along with the pioneering FUS-mediated gene delivery approaches[11,12,13,14,15]. FUS-mediated small-molecule delivery has been explored in animal models, these approaches either require BBB opening or are too inefficient[10,21,24] (see “Discussion”)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call